<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352339</url>
  </required_header>
  <id_info>
    <org_study_id>Aripiprazole study 2006</org_study_id>
    <nct_id>NCT00352339</nct_id>
  </id_info>
  <brief_title>The New Strategy for Pharmacological Treatment in People With Schizophrenia</brief_title>
  <official_title>Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate
      the same efficacy as compared to risperidone continuation treatment in the treatment of
      schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase
      of pharmacological treatment of patients with schizophrenia. However, this classical strategy
      produces long term adverse events of drug such as TD, osteoporosis and some metabolic
      syndrome. To overcome these adverse events, new strategy for pharmacological treatment is
      needed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SANS(Scale for the Assessment of Negative Symptoms)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS(Simpson-Angus Rating Scale)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Attitude Inventory</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect checklist</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switching group (from risperidone to aripiprazole)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start with risperidone and keep it through the end of study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abilify</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start with aripiprazole and keep it through the end of study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rispridoen and Aripiprazole</intervention_name>
    <description>Start with risperidone and switch it to aripiprazole. Flexible dose</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidne</intervention_name>
    <description>Start with risperidne and keep it through the end of study. Risperidne:flexible dose</description>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify</intervention_name>
    <description>Start with abilify and keep it through the end of study</description>
    <arm_group_label>Abilify</arm_group_label>
    <other_name>abilify is a generic name of aripiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia, DSM-IV

          -  Acute phase

        Exclusion Criteria:

          -  Refractory Schizophrenia

          -  Substance Abuse

          -  High risk for suicide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Cheol Shim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Center, Paik hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun-A Lee, MS</last_name>
    <phone>82-51-890-8955</phone>
    <email>euna066@nate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dongrae Hospital</name>
      <address>
        <city>Busan</city>
        <zip>609-370</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yung-Soo Seo, MD.PhD</last_name>
      <phone>82-51-508-0011</phone>
      <email>npsys@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Young-Soo Seo, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongseo Hospital</name>
      <address>
        <city>Masan</city>
        <zip>630-856</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-Un Jung, MD</last_name>
      <phone>82-016-579-2985</phone>
      <email>cgabriel@chol.com</email>
    </contact>
    <investigator>
      <last_name>Do-Un Jung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Busan Paik Hospital, Inje University</name_title>
    <organization>Clinical Trial Center</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Switching</keyword>
  <keyword>Early stage</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Aripirazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

